IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis

European Journal of Neurology

Volumn 12, Issue 3, 2005, Pages 171-175

  Wergeland, S ^a   Beiske, A ^b   Nyland, H ^a   Hovdal, H ^c   Jensen, D ^d   Larsen, J P ^e   Maroy T H ^a   Smievoll, A I ^a   Vedeler, C A ^a   Myhr, Kjell Morten ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Interferon; Interleukin 10 gene polymorphisms; Multiple sclerosis

Indexed keywords

ADENINE; BETA1A INTERFERON; GADOLINIUM; GUANINE; INTERLEUKIN 10; RECOMBINANT ALPHA2A INTERFERON; THYMINE;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RANK SUM TEST; RECURRENT DISEASE; REMISSION;

ADULT; BASE SEQUENCE; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FEMALE; GENETIC SCREENING; HAPLOTYPES; HUMANS; INTERFERONS; INTERLEUKIN-10; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 20044396374     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.01102.x     Document Type: Article

References (41)

1. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A (1993). Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240:417-422.
2. Bejarano MT, de Waal MR, Abrams JS et al. (1992). Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 4:1389-1397.
3. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK (1998). IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 161:3299-3306.
4. van Boxel-Dezaire AH, Hoff SC, van Oosten BW et al. (1999). Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 45:695-703.
5. Edwards-Smith CJ. Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999). Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526-530.
6. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998). Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 95:9465-9470.
7. Hurme M, Lahdenpohja N, Santtila S (1998). Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 30:469-473.
8. Issazadeh S, Lorentzen JC, Mustafa MI, Hojeberg B, Mussener A, Olsson T (1996). Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. J Neuroimmunol 69:103-115.
9. Jacobs LD, Cookfair DL, Rudick RA et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294.
10. de Jong BA, Schrijver HM, Huizinga TW et al. (2000). Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis, Ann Neurol 48:641-646.
11. Kennedy MK, Torrance DS, Picha KS, Mohler KM (1992). Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149:2496-2505.
12. Kurtzke JF (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452.
13. van der Linden MW, Huizinga TW, Stoeken DJ, Sturk A, Westendorp RG (1998). Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J Immunol Methods 218:63-71.
14. Luomala M, Lehtimaki T, Huhtala H et al. (2003). Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand 108:396-400.
15. Martinez DA, Rubio A, Arroyo R et al. (2002). Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J Neuroimmunol 131:168-172.
16. Maurer M, Kruse N, Giess R, Toyka KV, Rieckmann P (2000). Genetic variation at position -1082 of the interleukin 10 (IL10) promoter and the outcome of multiple sclerosis. J Neuroimmunol 104:98-100.
17. Moore KW, O'Garra A, de Waal MR, Vieira P, Mosmann TR (1993). Interleukin-10. Annu Rev Immunol 11:165-190.
18. Myhr KM, Ruse T, Green Lilleas FE et al. (1999). Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 52:1049-1056.
19. Myhr KM, Vagnes KS, Maroy TH, Aarseth JH, Nyland HI, Vedeler CA (2002). Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci 202:93-97.
20. Ozenci V, Kouwenhoven M, Huang YM, Kivisakk P, Link H (2000). Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferonbeta (IFN-beta) treatment. Clin Exp Immunol 120:147-153.
21. Panitch HS (1994). Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36(Suppl.):S25-S28.
22. Pawelec G, Pohla H, Schlotz E et al. (1995). Interleukin 10 is a human T cell growth factor in vitro. Cytokine 7:355-363.
23. Payvandi F, Amrute S, Fitzgerald-Bocarsly P (1998). Exogenous and endogenous IL-10 regulate IFN-alpha production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol 160:5861-5868.
24. Petereit HF, Pukrop R, Fazekas F et al. (2003). Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. J Neurol Sci 206:209-214.
25. Pickard C, Mann C, Sinnott P et al. (1999). Interieukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J Neuroimmunol 101:207-210.
26. Poser CM, Paty DW, Scheinberg L et al. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
27. PRISMS Study Group (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504.
28. Rieckmann P, Albrecht M, Kitze B et al. (1994). Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44:1523-1526.
29. Rothuizen LE, Buclin T, Spertini F et al. (1999). Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141.
30. Rudick RA, Ransohoff RM, Peppier R, VanderBrug MS, Lehmann P, Alam J (1996). Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 40:618-627.
31. Samoilova EB, Horton JL, Chen Y (1998). Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell Immunol 188:118-124.
32. Shen X, Hong F, Nguyen VA, Gao B (2000). IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 480:132-136.
33. Sibley WA, Bamford CR, Clark K (1985). Clinical viral infections and multiple sclerosis. Lancet 1:1313-1315.
34. Taga K, Cherney B, Tosato G (1993). IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 5:1599-1608.
35. The IFNB Multiple Sclerosis Study Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MA/MRI Analysis Group. Neurology 45:1277-1285.
36. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997). An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1-8.
37. de Waal-Malefyt R, Haanen J, Spits H et al. (1991). Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915-924.
38. Waubant E, Gee L, Bacchetti P et al. (2001). Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 112:139-145.
39. Westendorp RG, Langermans JA, Huizinga TW et al. (1997). Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170-173.
40. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA (2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33:708-712.
41. Yong VW (2002). Differential mechanisms of action of interferon-{beta} and glatiramer acetate in MS. Neurology 59:802-808.